(Q45857739)

17 December 2017

title

Tolerance induction using the Malmö treatment model 1982-1995. (English)

1 reference

17 December 2017

author name string

Freiburghaus C

1

1 reference

17 December 2017

Berntorp E

2

1 reference

17 December 2017

Ekman M

3

1 reference

17 December 2017

Gunnarsson M

4

1 reference

17 December 2017

Kjellberg B

5

1 reference

17 December 2017

Nilsson IM

6

1 reference

17 December 2017

publication date

1 January 1999

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

5

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

32-39

1 reference

17 December 2017

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Polymorphism of normal factor IX detected by mouse monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00195.X

10.1046/J.1365-2516.1999.00195.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017